Neo-adjuvant Chemotherapy Evluation in Gastric Cancer Patients Based on Circulating Exosomal LncRNA-GC1

Launched by CHINESE PLA GENERAL HOSPITAL · Dec 4, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a specific molecule called lncRNA-GC1 to see if it can help doctors understand how well a type of treatment called neo-adjuvant chemotherapy is working for patients with advanced gastric cancer, which is a common stomach cancer. The goal is to find a simple and non-invasive way to monitor treatment responses so that doctors can personalize care for their patients.

To participate in this study, you need to be at least 18 years old and have a confirmed diagnosis of advanced gastric adenocarcinoma, which is a type of stomach cancer. You will also need to sign a consent form agreeing to take part. However, if you have had another cancer in the last five years, had surgery recently (except for a biopsy), are pregnant or breastfeeding, or are legally unable to provide consent, you won’t be eligible. If you join the trial, you can expect to contribute to important research that could help improve treatment for gastric cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Having signed informed consent
• • Age≥ 18 years old
• • Histologically confirmed gastric adenocarcinoma
• • radiographically identified as advanced gastric cancer
• Exclusion Criteria:
• • Other previous malignancy within 5 year
• • Surgery (excluding diagnostic biopsy) within 4 weeks prior to study
• • Pregnancy or lactation period
• • Legal incapacity